Company logo

IPHA - Innate Pharma S.A.

NASDAQ -> Healthcare -> Biotechnology
Marseille, France

IPHA price evolution
IPHA
(in millions $) 30 Dec 2021 29 Sep 2021 29 Jul 2021 30 Mar 2021
Current assets
Cash $103.76 $103.76 $125.29 $103.98
Short term investments $16.08 $16.08 $15.34 $15.34
Net receivables $13.47 $13.47 $12.49 $3.6
Inventory
Total current assets $138.26 $138.26 $156.26 $129.69
Long term investments $39.88 $39.88 $40.08 $40.08
Property, plant & equipment $10.17 $10.17 $13.12 $10.89
Goodwill & intangible assets
Total noncurrent assets $164.5
Total investments
Total assets $267.5 $267.5 $320.76 $266.22
Current liabilities
Accounts payable $14.73 $14.73 $20.51 $11.18
Deferred revenue $12.61
Short long term debt $29.94 $29.94 $1.18 $1.18
Total current liabilities $79.89 $79.89 $51.35 $42.62
Long term debt $11.49 $11.49 $17.45 $12.03
Total noncurrent liabilities $108.49
Total debt
Total liabilities $160.06 $160.06 $159.84 $132.66
Shareholders' equity
Retained earnings -$272.21 -$272.21 -$294.18 -$244.15
Other shareholder equity $0.46 $0.46 $0.86 $0.72
Total shareholder equity $107.44 $107.44 $133.56 $133.56
(in millions $) 30 Dec 2021 30 Dec 2020 30 Dec 2019 30 Dec 2018
Current assets
Cash $103.76 $136.79 $202.89 $152.31
Short term investments $16.08 $14.85 $15.98 $15.22
Net receivables $13.47 $21.81 $18.74 $146.64
Inventory
Total current assets $138.26 $173.45 $237.6 $319.64
Long term investments $39.88 $38.93 $37.01 $35.18
Property, plant & equipment $10.17 $11.69 $11.67 $10.22
Goodwill & intangible assets
Total noncurrent assets $153.04 $183.41 $155.39
Total investments
Total assets $267.5 $307.42 $401.36 $451.22
Current liabilities
Accounts payable $14.73 $20.73 $27.94 $28.58
Deferred revenue $12.91 $54.62 $96.96
Short long term debt $29.94 $1.36 $1.49 $0.39
Total current liabilities $79.89 $45.49 $121.82 $196.74
Long term debt $11.49 $14.19 $14.1 $2.03
Total noncurrent liabilities $121.04 $69.58 $103.03
Total debt
Total liabilities $160.06 $151.45 $183.94 $283.98
Shareholders' equity
Retained earnings -$272.21 -$220.46 -$155.67 -$134.79
Other shareholder equity $0.46 $0.35 -$0.47 -$1.1
Total shareholder equity $107.44 $155.98 $217.42 $167.24
(in millions $) 31 Jan 2022 29 Sep 2021 29 Jul 2021 30 Mar 2021
Revenue
Total revenue $7.84
Cost of revenue $10.9
Gross Profit -$3.05
Operating activities
Research & development
Selling, general & administrative $9.66
Total operating expenses $20.56
Operating income -$12.71
Income from continuing operations
EBIT -$12.71
Income tax expense
Interest expense -$0.08
Net income
Net income -$11.86
Income (for common shares) -$11.86
(in millions $) 30 Dec 2021 30 Dec 2020 30 Dec 2019 30 Dec 2018
Revenue
Total revenue $24.7 $70.45 $85.81 $93.95
Cost of revenue $47 $58.61 $78.84 $69.56
Gross Profit -$22.3 $11.84 $6.97 $24.4
Operating activities
Research & development
Selling, general & administrative $25.52 $31.25 $25.8 $18.14
Total operating expenses $72.53 $89 $112.87 $88.81
Operating income -$47.83 -$18.55 -$27.05 $5.15
Income from continuing operations
EBIT -$47.83 -$18.55 -$27.05 $5.15
Income tax expense -$0.33
Interest expense -$0.31 -$0.34 -$0.2 -$0.1
Net income
Net income -$52.81 -$63.98 -$20.76 $3.05
Income (for common shares) -$52.81 -$63.98 -$20.76 $3.05
(in millions $) 30 Dec 2021 29 Sep 2021 29 Jul 2021 30 Mar 2021
Net income -$28.58 -$11.86
Operating activities
Depreciation $1.08
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$37.55 -$15.58
Investing activities
Capital expenditures -$0.12
Investments
Total cash flows from investing -$0.3 -$0.12
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings -$0.56
Total cash flows from financing -$1.48 -$0.61
Effect of exchange rate -$0.21 -$0.09
Change in cash and equivalents -$39.54 -$16.41
(in millions $) 30 Dec 2021 30 Dec 2020 30 Dec 2019 30 Dec 2018
Net income -$52.81 -$63.98 -$20.76 $3.05
Operating activities
Depreciation $4.6 $13.27 $16.53 $7.34
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$58.46 -$51.77 $34.92 -$32.53
Investing activities
Capital expenditures -$0.93 -$0.91 -$1.27 -$0.87
Investments -$3 $2 $24.22
Total cash flows from investing -$0.92 -$13.37 -$62.12 $24.28
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings $26.63 -$0.89 $11.92 -$1.34
Total cash flows from financing $26.82 -$1.18 $77.77 $61.22
Effect of exchange rate -$0.48 $0.22 $0.01 -$0.03
Change in cash and equivalents -$33.04 -$66.1 $50.57 $52.95
Fundamentals
Market cap $230.50M
Enterprise value N/A
Shares outstanding 79.48M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio 2.15
Book/Share 1.35
Cash/Share 1.31
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.49
Net debt/EBITDA N/A
Current ratio 1.73
Quick ratio N/A